These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 37239930

  • 1. Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.
    Sarafanov AG.
    Int J Mol Sci; 2023 May 11; 24(10):. PubMed ID: 37239930
    [Abstract] [Full Text] [Related]

  • 2. Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A.
    Konkle BA.
    Expert Rev Hematol; 2023 May 11; 16(8):567-573. PubMed ID: 37289594
    [Abstract] [Full Text] [Related]

  • 3. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
    Pipe S, Sadeghi-Khomami A, Konkle BA, Kitchen S, Negrier C, Liu M, Santagostino E, Willemze A, Abad-Franch L, Knobe K, Seth Chhabra E.
    Haemophilia; 2024 Jan 11; 30(1):214-223. PubMed ID: 37902390
    [Abstract] [Full Text] [Related]

  • 4. Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A.
    Abdelgawad HAH, Foster R, Otto M.
    Blood Rev; 2024 Mar 11; 64():101164. PubMed ID: 38216442
    [Abstract] [Full Text] [Related]

  • 5. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
    Elsheikh E, Lavin M, Heck LA, Larkin N, Mullaney B, Doherty D, Kennedy M, Keenan C, Guest T, O'Mahony B, Fazavana J, Fallon PG, Preston RJS, Gormley J, Ryan K, O'Connell NM, Singleton E, Byrne M, McGowan M, Roche S, Doyle M, Crowley MP, O'Shea SI, Reipert BM, Johnsen JM, Pipe SW, Di Paola J, Turecek PL, O'Donnell JS, iPATH study group.
    J Thromb Haemost; 2023 May 11; 21(5):1123-1134. PubMed ID: 36775768
    [Abstract] [Full Text] [Related]

  • 6. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.
    Demers M, Aleman MM, Kistanova E, Peters R, Salas J, Seth Chhabra E.
    J Thromb Haemost; 2022 Jul 11; 20(7):1674-1683. PubMed ID: 35466511
    [Abstract] [Full Text] [Related]

  • 7. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD, Chelle P, Clarke E, Kim L, Tiseo L, Morfini M, Hossain T, Rand ML, Brown C, Edginton AN, Lillicrap D, Iorio A, Blanchette VS.
    J Thromb Haemost; 2019 Jul 11; 17(7):1085-1096. PubMed ID: 31038793
    [Abstract] [Full Text] [Related]

  • 8. Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia.
    Turecek PL, Johnsen JM, Pipe SW, O'Donnell JS, iPATH study group.
    Haemophilia; 2020 Jul 11; 26(4):575-583. PubMed ID: 32596930
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A, Moonla C, Sosothikul D.
    Haemophilia; 2023 Jan 11; 29(1):156-164. PubMed ID: 36409282
    [Abstract] [Full Text] [Related]

  • 10. Perspective - The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021.
    Di Minno A, Spadarella G, Esposito S, Mathew P, Di Minno G, Mannucci PM.
    Blood Rev; 2021 Nov 11; 50():100849. PubMed ID: 34024681
    [Abstract] [Full Text] [Related]

  • 11. Efanesoctocog alfa: the renaissance of Factor VIII replacement therapy.
    Dargaud Y, Leuci A, Ruiz AR, Lacroix-Desmazes S.
    Haematologica; 2024 Aug 01; 109(8):2436-2444. PubMed ID: 38356459
    [Abstract] [Full Text] [Related]

  • 12. A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B.
    Abraham S, Duncan EM.
    Methods Mol Biol; 2023 Aug 01; 2663():569-588. PubMed ID: 37204737
    [Abstract] [Full Text] [Related]

  • 13. Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021.
    Abbattista M, Ciavarella A, Noone D, Peyvandi F.
    J Thromb Haemost; 2023 Mar 01; 21(3):546-552. PubMed ID: 36710195
    [Abstract] [Full Text] [Related]

  • 14. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
    Müller J, Goldmann G, Marquardt N, Pötzsch B, Oldenburg J.
    Hamostaseologie; 2020 Nov 01; 40(S 01):S15-S20. PubMed ID: 33187006
    [Abstract] [Full Text] [Related]

  • 15. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
    Carcao M, Zunino L, Young NL, Dover S, Bouskill V, Hilliard P, Price VE, Blanchette VS.
    Haemophilia; 2020 Jan 01; 26(1):73-78. PubMed ID: 31865620
    [Abstract] [Full Text] [Related]

  • 16. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.
    Srichumpuang C, Rakmanotham A, Moonla C, Sosothikul D.
    Orphanet J Rare Dis; 2024 Mar 26; 19(1):135. PubMed ID: 38532451
    [Abstract] [Full Text] [Related]

  • 17. Laboratory monitoring of new hemostatic agents for hemophilia.
    Pruthi RK.
    Semin Hematol; 2016 Jan 26; 53(1):28-34. PubMed ID: 26805904
    [Abstract] [Full Text] [Related]

  • 18. Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays.
    Peyvandi F, Kenet G, Pekrul I, Pruthi RK, Ramge P, Spannagl M.
    J Thromb Haemost; 2020 Jun 26; 18(6):1242-1255. PubMed ID: 32115865
    [Abstract] [Full Text] [Related]

  • 19. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V, Lehtinen AE, Iorio A, Szanto T, Lassila R.
    Haemophilia; 2022 Nov 26; 28(6):e237-e244. PubMed ID: 35939628
    [Abstract] [Full Text] [Related]

  • 20. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P, Kiehl R, Miyashita C, Schwerdt H, von Blohn G, Köhler M, Büttner M, Wenzel E.
    Thromb Haemost; 1986 Dec 15; 56(3):353-9. PubMed ID: 3105109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.